Several analysts have recently updated their ratings and price targets for Inovio Pharmaceuticals (NASDAQ: INO):
- 11/12/2026 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
- 11/11/2026 – Inovio Pharmaceuticals had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 11/11/2026 – Inovio Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $6.00 price target on the stock, down from $8.00.
- 11/6/2026 – Inovio Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $8.00 price target on the stock, up from $3.00.
- 11/2/2026 – Inovio Pharmaceuticals was given a new $5.00 price target by HC Wainwright. They now have a “buy” rating on the stock.
- 11/2/2026 – Inovio Pharmaceuticals was upgraded by HC Wainwright from “neutral” to “buy”.
- 10/12/2026 – Inovio Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
Inovio Pharmaceuticals Stock Performance
Shares of INO stock traded up $0.23 on Tuesday, hitting $1.63. 15,602,997 shares of the stock traded hands, compared to its average volume of 27,654,768. Inovio Pharmaceuticals, Inc. has a twelve month low of $0.56 and a twelve month high of $2.72. The firm’s 50-day moving average price is $1.19 and its two-hundred day moving average price is $1.27. The stock has a market capitalization of $179.59 million, a PE ratio of -3.02 and a beta of 1.71.
Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.29). The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $2.27 million. On average, equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -0.97 EPS for the current fiscal year.
Read More
- Five stocks we like better than Inovio Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
